Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Clicks: 188
ID: 116826
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
188 views
26 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #228 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Monotherapy with lefamulin, a novel, pleuromutilin antibiotic with intravenous and oral formulation options, was noninferior to moxifloxacin for efficacy and ge
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (21 words).
Try re-searching for a better abstract.
| Reference Key |
m2019clinicalefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | File, Thomas M;Goldberg, Lisa;Das, Anita;Sweeney, Carolyn;Saviski, John;Gelone, Steven P;Seltzer, Elyse;Paukner, Susanne;Wicha, Wolfgang W;Talbot, George H;Gasink, Leanne B; |
| Journal | clinical infectious diseases |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.